Publicaciones de Juan José Gagliardino

2016

  • Frequency of self-monitoring blood glucose and attainment of HbA1c target values. Elgart JF, González L, Prestes M, Rucci E, Gagliardino JJ. Acta Diabetologica. Feb; 53(1):57-62. doi: 10.1007/s00592-015-0745-9 (ISSN: 0940-5429).
  • Primary prevention of type 2 diabetes in Argentina: Pilot study in the province of Buenos Aires. Juan José Gagliardino, Graciela Etchegoyen, Marcelo Bourgeois, Gabriel Fantuzzi, Silvia García, Lorena González, Jorge Federico Elgart, Matías Ré, Alberto Ricart, Juan Pablo Ricart, Eduardo Spinedi. Revista Argentina de Endocrinología y Metabolismo 53:135-141, 2016.
  • Dapagliflozin versus Sulfonylurea as an add-on therapy to Metformin: a Cost-effectiveness analysis in Costa Rica. Elgart JF, Gonzalez L, Prestes M, Vinocour M, Solorzano J, Gagliardino JJ. ISPOR 21st International Meeting, Washington, USA. Value in Health. 2016; 19(3):A202.
  • Cost-effectiveness of Dapagliflozin in the treatment of type 2 diabetes mellitus in Peru. Elgart JF, Gonzalez L, Prestes M, Manrique H, Solorzano J, Gagliardino JJ. ISPOR 21st International Meeting, Washington, USA. Value in Health. 2016; 19(3):A203.
  • Cost of type 2 diabetes treatment in Latin America: effect of degree of metabolic control. Elgart JF, Gonzalez L, Prestes M, Gagliardino JJ. ISPOR 21st International Meeting, Washington, USA. Value in Health. 2016; 19(3):A201.
  • Dapagliflozin: Cost effectiveness as an add-on therapy to metformin in the treatment of type 2 diabetes in Ecuador. Elgart JF, Prestes M, Gonzalez L, Solis Sanchez C, Acosta W, Solorzano J, Gagliardino JJ. ISPOR 21st International Meeting, Washington, USA. Value in Health. 2016; 19(3):A202.
  • Resultados preliminares del programa piloto de prevención primaria de diabetes en la Provincia de Buenos Aires (PPDBA). Gagliardino J, Etchegoyen G, Spinedi E, Bourgeois M, Elgart J, Fantuzzi G, García S, González C, González L, Re M, Ricart A, Ricart J. XX Congreso Argentino de Diabetes, Sociedad Argentina de Diabetes (SAD). Revista de la SAD. 2016.
  • Impacto del grado de control metabólico sobre el costo del tratamiento Farmacológico de la diabetes tipo 2 en Argentina. Elgart JF, González L, Prestes M, Gagliardino JJ. XX Congreso Argentino de Diabetes, Sociedad Argentina de Diabetes (SAD). Revista de la SAD. 2016.
  • Cost-effectiveness of dapagliflozin as an add-on therapy to metformin in the treatment of type 2 diabetes (T2DM) in the Dominican Republic and Guatemala. Elgart JF, Prestes M, Gonzalez L, Solorzano J, Gagliardino JJ. ISPOR 19th Annual Europena Congress. Value in Health, 2016; 19(7):A671–A672.

2015

  • Role of Islet Glucokinase, Glucose Metabolism, and Insulin Pathway in the Enhancing Effect of Islet Neogenesis-Associated Protein on Glucose-Induced Insulin Secretion. Maiztegui B, Román CL, Barbosa-Sampaio HC, Boschero AC, Gagliardino JJ. Pancreas. 2015 Apr 21.
  • Fructose-induced inflammation, insulin resistance and oxidative stress: a liver pathological triad effectively disrupted by lipoic acid. Castro MC, Massa ML, González Arbeláez L, Schinella G, Gagliardino JJ, Francini F. Life Sciences, 137 (2015): 1-6.
  • Educación de personas con diabetes tipo 2: ¿Es costo efectiva su implementación a través de pares con diabetes?. Gonzalez L, Elgart JF, Gagliardino JJ. Medwave Medwave. Dec; 15(11):e6348. doi: 10.5867/medwave.2015.11.6348 (ISSN: 0717-6384).
  • Análisis de Costo-Efectividad de la Educacion de pacientes con Diabetes Tipo 2 por Pares. Gonzalez L, Elgart JF, Prestes M, Gagliardino JJ. ISPOR 5th Latin America Conference, Santiago, Chile. Value in Health. 2015; 18(7):A864-865
  • Impacto Presupuestario de Incorporar Linagliptina para el tratamiento de la Diabetes en Argentina. Elgart JF, Prestes M, Gonzalez L, De los Santos MC, Gagliardino JJ. ISPOR 5th Latin America Conference, Santiago, Chile. Value in Health. 2015; 18(7):A863
  • Body mass index impact on treatment costs in people with type 2 diabetes in Latin America. Elgart JF, Gonzalez L, Rucci E, Gagliardino JJ. IDF World Diabetes Congress, Vancouver, Canadá.

2014

  • Diabetes in South and Central America: An update for 2013 for the IDF Diabetes Atlas. Aschner P, Aguilar-Salinas C, Aguirre L, Franco L, Gagliardino JJ, de Lapertosa SG, Seclen S, Vinocour M; on behalf of the IDF Diabetes Atlas. Diabetes Res Clin Pract. 2014; 103:238-243.
  • Lipoic acid prevents fructose-induced changes in liver carbohydrate metabolism: Role of oxidative stress. Castro MC, Francini F, Gagliardino JJ, Massa ML. Biochim Biophys Acta. 2014;1840(3):1145-51.
  • Association between socioeconomic status, type 2 diabetes and its chronic complications in Argentina. Elgart JF, Caporale JE, Asteazarán S, De La Fuente JL, Camilluci C, Brown JB, González CD, Gagliardino JJ. Diabetes Res Clin Pract. 2014;104(2):241-7. doi: 10.1016/j.diabres.2014.02.010.
  • Call-to-action: Timely and appropriate treatment for people with type 2 diabetes in Latin America. Escalante M, Gagliardino JJ, Guzmán JR, Tschiedel B. Diabetes Res Clin Pract. 2014;pii: S0168-8227(14)00006-0. doi: 10.1016/j.diabres.2014.01.004.
  • Calidad de atención de personas con diabetes tipo 2 en Latinoamérica: ¿hay evidencia de disparidad de género? Wandurraga EA, Villena Chávez J, Stepenka V, Solis CL, Ramirez de Peña D, Perez Manghi F, Padron MA, Manrique H, Lujan D, Lapertosa S, Gonzalez J, Fuente G, Faingold MC, Commendatore V, Aschner P, Gonzalez L, Elgart JF, Gagliardino JJ, DIFAR Academic Committee. Revista ALAD Vol 4 Nº 3. 2014.
  • Direct and indirect costs associated to type 2 diabetes and its complications measured in a social security institution of Argentina. Elgart J; Asteazaran S; de la Fuente J; Camillucci C; Brown JB; Gagliardino JJ. International journal of public health Basel: Birkhauser Verlag AG, 2014. vol. 59, p. 851-857. ISSN 1661-8556
  • Global Guideline for Type 2 Diabetes. International Diabetes Federation Guideline Development Group; Gagliardino JJ et al. Diabetes research and clinical practice. Amsterdam: ELSEVIER Ireland Ltd, 2014. vol. 104, p. 1-52. ISSN 0168-8227
  • Verse bien y sentirse mejor. Guía para lograr una vida activa y saludable. Gagliardino JJ; Kronsbein P; Ricart A; Sabugal J; Alvarez A; Guinsbourg M; García S. Magenta, 2014. p. 1. ISBN 978-987-45375-08
  • Aumento de la masa de células B inducida por Ingap-PP: Participación de la angionénesis insular. Roman CL; Maiztegui B; Flores L; Gagliardino JJ. Resumen. Congreso. XIX Congreso Argentino de Diabetes, Diabetes un debate constante. Mar del Plata. 2014. Sociedad Argentina de Diabetes (SAD).
  • Autofagia y apoptosis de las células B inducidas por dieta rica en fructosa: Efecto preventivo de las incretinas. Maiztegui, B.; Roman, C. L.; Boggio, V.; Flores, L. E.; Del Zotto, H.; Ropolo, A; Grasso D.; Fabiano, L.E.; Vaccaro, M. I.; Gagliardino, J. J. Resumen. Congreso. XIX Congreso Argentino de Diabetes, Diabetes un debate constante. Mar del Plata. 2014. Sociedad Argentina de Diabetes (SAD).
  • Automonitoreo glucémico: utilización y costo según tipo de medicación y grado de control metabólico en la seguridad social argentina. Gonzalez Lorena; Elgart Jorge; Rucci Enzo; Prestes Mariana; Gagliardino JJ. Resumen. Congreso. XIX Congreso Argentino de Diabetes, Sociedad Argentina de Diabetes (SAD). Mar del Plata. 2014.
  • Calidad de atención de personas con diabetes tipo 2 en argentina (QUALIDIAB): ¿Prescribimos y logramos metas terapéuticas recomendadas en nuestros pacientes?. Faingold MC; Lapertosa S; Fuente G; Perez Manghi F; Gonzalez J; Commendatore V; De Carolis S; Rueda S; Urdangarin R; Sosa L; Gonzalez Lorena; Elgart Jorge; Gagliard
  • Dapagliflozin versus sulfonylurea as an add-on therapy to metformin: a cost-effectiveness analysis in Colombia. Elgart Jorge; Prestes Mariana; Gonzalez Lorena; Aschner P; Garrido Lecca S; Aiello Eleonora; Jimenez C; Gagliardino JJ. Resumen. Congreso. ISPOR 19th International Meeting. 2014.
  • Efecto de la Inhibición Angiogénica sobre las células progenitoras adipocitarias y adipocitos del tejido adiposo visceral. Fariña JP; García María E; Zubiria G; Giovambattista A; Spinedi E; Gagliardino JJ. Resumen. Congreso. SAD 2014. Mar del Plata. 2014. SAD.
  • Effect of Incretins upon B-Cell Autophagy and Apoptosis Induced by a Fructose-Rich Diet. Roman CL; Boggio V; Maiztegui B; Flores L; Del Zotto H; Ropolo A; Grasso D; Catrinacio C; Vaccaro MI; Gagliardino JJ. Resumen. Congreso. 74th Scientific Sessions American Diabetes Association (ADA). San Francisco. 2014-. American Diabetes Association.
  • Endogenous Sex Steroid-Dependent in Vitro Rat Adipogenesis. Martín MF; Fariña JP; Castrogiovanni D; Giovambattista A; Gagliardino JJ; Spinedi E. Resumen. Congreso. ICE/ENDO 2014. Chicago. 2014. ESO.
  • Oxidative stress mediates metabolic and endocrine dysfunctions induced by fructose. Castro MC; Francini F; Schinella G; Gonzalez Arbelaez LF; Gagliardino JJ; Massa ML. Resumen. Congreso. XXIII Congreso de la Asociación Latinoamericana para el Estudio del Hígado. México. 2014.
  • Papel modulador del tejido adiposo prevascular sobre la contractilidad del músculo liso vascular. Fariña JP; García ME; Marra C; Gagliardino JJ; Rinaldi G. Resumen. Congreso. LIX Reunión Científica Anual Sociedad Argentina de Investigación Clínica y LXII Reunión anual Sociedad Argentina de Inmunología. 2014.
  • Saxagliptin/metformin extended-release (xr) for the type 2 diabetes (T2DM) treatment in Venezuela: a budget impact analysis. Elgart Jorge; Gonzalez Lorena; Perez Monteverde; Garrido Lecca S; Aiello Eleonora; Gagliardino JJ. Resumen. Congreso. ISPOR 19th International Meeting, Montreal, Canadá. 2014.
  • Islet NADPH oxidase activity modulates B-cell mass andendocrine function in rats with fructose-induced oxidative stress. Román CL; Flores LE; Maiztegui B; Raschia MA; Del Zotto H; Gagliardino JJ; Biochimica et biophysica acta-general subjects. Amsterdam: ELSEVIER Science BV, 2014. vol. 1840, p. 3475-3482. ISSN 0304-4165
  • Self-Monitoring of Blood Glucose: use, frequency drivers, and cost in Argentina. Jorge Elgart; Lorena Gonzalez; Enzo Rucci; Juan José Gagliardino. Journal of diabetes Science and technology California: SAGE Journals, 2014. vol. 8, n° 6, p. 1121-1125. ISSN 1932-2968
  • The Burden of Diabetes in Argentina. Gonzalez Lorena; Caporale Joaquín; Elgart Jorge; Gagliardino JJ. Global journal of health Science. Canadian Center of Science and Education, 2014. vol. 7, n° 3, p. 124-133. ISSN 1916-9736
  • Dapagliflozin: cost-effectiveness as an add-on therapy to metformin in the treatment of type 2 diabetes (T2DM) in Argentina and Chile. Elgart JF, Prestes M, Gonzalez L, Asteazaran S, Aiello E, Garrido Lecca S, Alvarez A, Roberts M, Cortes Cuadra P, Gagliardino JJ. ISPOR 19th International Meeting, Montreal, Canadá. Value in Health. 2014; 17(3):A248.
  • Costos Directos e Indirectos asociados a la Diabetes Tipo 2 y sus complicaciones medidos en la Seguridad Social. Elgart J, Asteazaran S, De La Fuente J, Camillucci C, Gagliardino JJ. XIX Congreso Argentino de Diabetes, Sociedad Argentina de Diabetes (SAD). Revista de la SAD. 2014; 48:60-61.

2013

  • Lipoic acid prevents liver metabolic changes induced by administration of a fructose-rich diet.Castro MC, Massa ML, Schinella G, Gagliardino JJ, Francini F. Biochim Biophys Acta. 2013;1830:2226– 2232.
  • Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina. Elgart JF, Caporale JE, Gonzalez L, Aiello E, Waschbusch M, Gagliardino JJ. Health Econ Rev. 2013 Apr 27;3(1):11.
  • Antioxidant treatment prevents the development of fructose-induced abdominal adipose tissue dysfunction. Fariña JP, García ME, Alzamendi A, Giovambattista A, Marra CA, Spinedi E, Gagliardino JJ. Clin Sci (Lond). 2013 Jul 1;125(2):87-97.
  • Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review. Davies MJ, Gagliardino JJ, Gray LJ, Khunti K, Mohan V, Hughes R. Diabet Med. 2013 May;30(5):512-24.
  • Islet neogenesis-associated protein (INGAP)-positive cell mass, Beta-cell mass, and insulin secretion: their relationship during the fetal and neonatal periods. Madrid V, Borelli MI, Maiztegui B, Flores LE, Gagliardino JJ, Zotto HD. Pancreas. 2013 Apr;42(3):422-8.
  • Type 2 diabetes patients educated by other patients perform at least as well as patients trained by professionals. Gagliardino JJ, Arrechea V, Assad D, Gagliardino GG, González L, Lucero S, Rizzuti L, Zufriategui Z, Clark C Jr. Diabetes Metab Res Rev. 2013 Feb;29(2):152-60.
  • BRIDGES Research Net. Testing a new approach to translate research achievements into improved quality of care worldwide. Gagliardino JJ. Diabetes Voice 2013;58(1):29-32.
  • Clinical, metabolic and psychological outcomes and treatment costs of a prospective-randomized trial based on different educational strategies to improve diabetes care (PRODIACOR). JJ Gagliardino, S Lapertosa, G Pfirter, M Villagra, JE Caporale, CD Gonzalez, J Elgart, L González, C Cernadas, E Rucci, Ch Clark Jr, on behalf of the PRODIACOR. Diabet Med. 2013 Sep;30(9):1102-11. doi: 10.1111/dme.12230. Epub 2013 Jun 7.
  • Islet Cannabinoid Receptors: Cellular Distribution and Biological Function. LE Flores, ME Alzugaray, MA Cubilla, MA Raschia, HH Del Zotto, CL Román, AM Suburo, JJ Gagliardino. Pancreas. 2013 Oct;42(7):1085-92. doi: 10.1097/MPA.
  • Changes in quality of care and costs induced by implementation of a diabetes program in a social security entity of Argentina. González L, Elgart JF, Calvo H, Gagliardino JJ. Clinicoecon Outcomes Res. 2013 Jul 4;5:337-45. doi: 10.2147/CEOR.S40949. Print 2013.
  • Registry of people with diabetes in three Latin American countries: a suitable approach to evaluate the quality of health care provided to people with type 2 diabetes. V Commendatore, G Dieuzeide, C Faingold, G Fuente, D Luján, P Aschner, S Lapertosa, J Villena Chávez, J Elgart, and DIFAR Academic Committee. Int J Clin Pract. 2013 Dec;67(12):1261-6. doi: 10.1111/ijcp.12208.
  • Self-monitoring blood glucose: strips consumption rate and costs in Argentina. Elgart JF, Gonzalez L, Rucci E, Gagliardino JJ. ISPOR 18th Annual International Meeting, May 2013.
  • Type 2 diabetes: burden of the disease and out-of-pocket expenditures in Argentina. Elgart JF, Gonzalez L, Caporale JE, De la fuente JL, Camilluci C, Gagliardino JJ. ISPOR 18th Annual International Meeting, May 2013.
  • Budget Impact Analysis of the introduction of saxagliptin/metformin extended-release (XR) in the treatment of type 2 diabetes in Chile. Elgart JF, Gonzalez L, Aiello EC, Gagliardino JJ. ISPOR 18th Annual International Meeting, May 2013.
  • Excess fructose intake-induced hypertrophic visceral adipose tissue results from unbalanced precursor cell adipogenic signals. Zubiría MG, Fariña JP, Moreno G, Gagliardino JJ, Spinedi E, Giovambattista A. FEBS J. 2013 Sep 2. doi: 10.1111/febs.12511
  • Burden of Type 2 Diabetes and Out-of-Pocket Expenditures in Argentina. J Elgart, L González, S Asteazarán, Je Caporale, J De La Fuente, C Camillucci, JJ Gagliardino. 73rd American Diabetes Association Scientific Session. Chicago, 21-25 de junio 2013.
  • PI3K Mediates Islet Neogenesis-Associated Protein Effect upon ?-Cell Function. B Maiztegui, Cl Román, MI Borelli, JJ Gagliardino. 73rd American Diabetes Association Scientific Session. Chicago, 21-25 de junio 2013.
  • Self-Monitoring Blood Glucose: Treatment Dependence on Strip Consumption and Costs. J Elgart, L González, E Rucci, JJ Gagliardino. 73rd American Diabetes Association Scientific Session. Chicago, 21-25 de junio 2013.
  • Direct medical costs of treating diabetes related complications in Argentina. Elgart J; De la Llave G; Camillucci C; Vega-Hernandez G; Watkins M; Hammerby E; Nikolajsen A, Gagliardino JJ. ISPOR 4th Latin American Conference. Buenos Aires, 12-14 de septiembre 2013.
  • Impacto de la diabetes sobre la productividad en Argentina. Asteazaran S;Elgart J,Gagliardino JJ. ISPOR 4th Latin American Conference. Buenos Aires, 12-14 de septiembre 2013.
  • Costo del automonitoreo glucémico en pacientes en tratamiento combinado oral y con insulina en Argentina. Elgart J; Gonzalez L; Gagliardino JJ, Rucci E. ISPOR 4th Latin American Conference. Buenos Aires, 12-14 de septiembre 2013.
  • Relación del índice de masa corporal y gasto en medicamentos en personas con diabetes en Argentina. Prestes M; Elgart J; Gonzalez L, Gagliardino JJ. ISPOR 4th Latin American Conference. Buenos Aires, 12-14 de septiembre 2013.
  • Treatment of type 2 diabetes with saxagliptin/metformin extended-release (XR): budget impact analysis in Argentina. Elgart J, Gonzalez L, Aiello EC, Gagliardino JJ. ISPOR 4th Latin American Conference. Buenos Aires, 12-14 de septiembre 2013.
  • Relationship between islet angiogenesis and the positive effect of islet neogenesis-associated protein pentadecapeptide (INGAP-PP) upon beta cell function. LE Flores, CL Román, B Maiztegui, JJ Gagliardino. Diabetologia 2013, 56(Suppl.1): S195. 49th EASD Annual Meeting. Barcelona, 23-27 de septiembre 2013.
  • INGAP effect on pancreatic islet function: its potential molecular mechanism. B Maiztegui, C Román, JJ Gagliardino. Diabetologia 2013, 56(Suppl.1): S195. 49th EASD Annual Meeting. Barcelona, 23-27 de septiembre 2013.
  • Liver fructokinase: a new target for GLP-1 receptor agonists. F Francini, ML Massa, MC Castro, MP Polo, JJ Gagliardino. Diabetologia 2013, 56(Suppl.1): S280. 49th EASD Annual Meeting. Barcelona, 23-27 de septiembre 2013.
  • Lixisenatide significantly increases the probability of a A1C response in patients not adequately controlled on oral antihyperglycemic agents. Sigalas J, Bonadonna R, Puig-Domingo M, Roussel R, Wang E, Lin J, Gagliardino JJ, Rosenstock J. Can J Diabetes. 2013;37S4:S43. doi: 10.1016/j.jcjd.2013.08.124. 16th Annual Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meetings, Montreal, Quebec October 17 – 20, 2013.
  • La coadministración de exendina-4 y sitagliptina previene los cambios hepáticos inducidos por administración de fructosa, inhibiendo la actividad de fructoquinasa via receptor de glucagon like peptide-1. F. Francini, ML Massa, MC Castro, MP Polo, JJ Gagliardino. XV Congreso de la Asociación Latinoamericana de Diabetes. Cancún. 12-15 de noviembre 2013.
  • Conocimientos acerca de la diabetes y los riesgos de desarrollarla en América Latina: datos en población Argentina. Martín Rodríguez, et al. XV Congreso de la Asociación Latinoamericana de Diabetes. Cancún. 12-15 de noviembre 2013.
  • Conocimientos de personas con diabetes de América Latina sobre su enfermedad: situación en Argentina. Martín Rodríguez, et al. XV Congreso de la Asociación Latinoamericana de Diabetes. Cancún. 12-15 de noviembre 2013.
  • ARETAEUS: estudio retrospectivo sobre patrones de uso de medicamentos luego del diagnostico de diabetes mellitus tipo 2 en latinoamérica. Resultados en poblacion mexicana. R Arechavaleta Granell, et al. XV Congreso de la Asociación Latinoamericana de Diabetes. Cancún. 12-15 de noviembre 2013.
  • Rol de la angiogénesis en el efecto potenciador del INGAP-PP sobre la secreción de insulina. Lisi Román Carolina, Maiztegui Bárbara, Flores Luis Emilio, Gagliardino Juan José. XV Congreso de la Asociación Latinoamericana de Diabetes. Cancún. 12-15 de noviembre 2013.
  • Encuesta GAPP2 en Argentina: irregularidades en la dosificación de insulina y automanejo de la hipoglucemia en personas con diabetes tipo 2 tratadas con insulina. Juan José Gagliardino. XV Congreso de la Asociación Latinoamericana de Diabetes. Cancún. 12-15 de noviembre 2013.
  • Utilization rate and cost of test strips for self-monitoring blood glucose in the social security system of Argentina. Elgart JF, González L, Rucci E And Gagliardino JJ. IDF Congress, Melbourne December 2013.
  • Diabetes in Argentina: cost and management of diabetes and its complications and challenges for health policy. Caporale JE, Elgart JF, Gagliardino JJ. Global Health 2013; 9:54.